Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 10, 2026, 2:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 3,763 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Diabetes Mellitus Type 2 Clear all
Completed Phase 1Phase 2 Interventional

Effect of Different Doses of Salacinol Extract on Glycemic and Insulinemic Response in Patients With Type 2 Diabetes

NCT00306072
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
nutritional herbal extract from Salacia oblonga
Drug
Lead sponsor
Ross Products
Industry
Eligibility
18 Years to 75 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
2
States / cities
Edina, Minnesota • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 27, 2010 · Synced Oct 10, 2026, 2:35 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes

NCT03495102
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Dulaglutide
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,842 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
72
States / cities
Chandler, Arizona • Mesa, Arizona • Phoenix, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2020 · Synced Oct 10, 2026, 2:35 PM EDT
Completed Phase 3 Interventional

Treatment for Symptomatic Peripheral Neuropathy in Patients With Diabetes

NCT00044395
View directory record Official record
Conditions
Diabetic Neuropathies, Diabetes Mellitus, Insulin-Dependent, Diabetes Mellitus, Non-Insulin-Dependent
Interventions
Ruboxistaurin mesylate
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
19
States / cities
Mesa, Arizona • Irvine, California • Los Angeles, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2007 · Synced Oct 10, 2026, 2:35 PM EDT
Completed Phase 3 Interventional Results available

Telmisartan Fixed Dose Combination vs Amlodipine in Hypertensive Patients With Type 2 Diabetes Mellitus

NCT00877929
View directory record Official record
Conditions
Hypertension
Interventions
Telmisartan 80, Amlodipine 10
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
706 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
15
States / cities
Long Beach, California • Tustin, California • Fort Lauderdale, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2014 · Synced Oct 10, 2026, 2:35 PM EDT
Completed Phase 2 Interventional

Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy

NCT00476931
View directory record Official record
Conditions
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Polyneuropathy
Interventions
SB-509, Placebo
Biological · Other
Lead sponsor
Sangamo Therapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
19
States / cities
La Jolla, California • Lakewood, California • Lomita, California + 15 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2012 · Synced Oct 10, 2026, 2:35 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate Safety, Tolerability and P-Glucose After Multiple Ascending Oral Doses of AZD1656 in Type 2 Diabetes

NCT00747175
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
AZD1656
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
30 Years to 75 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Chula Vista, California
Source: ClinicalTrials.gov public record
Updated Dec 3, 2010 · Synced Oct 10, 2026, 2:35 PM EDT
Terminated Phase 2 Interventional

Long-term Extension Study to Evaluate the Safety of Dutogliptin/PHX1149T in Subjects With Type 2 Diabetes Mellitus

NCT01101945
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
dutogliptin
Drug
Lead sponsor
Phenomix
Industry
Eligibility
18 Years to 75 Years
Enrollment
339 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
27
States / cities
Fullerton, California • Long Beach, California • Orange, California + 24 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2010 · Synced Oct 10, 2026, 2:35 PM EDT
Completed Not applicable Interventional

Internet Diabetes Self-Management Workshop

NCT00185601
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Internet Diabetes Self-Management Program
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
761 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2013 · Synced Oct 10, 2026, 2:35 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Transform: Teaching, Technology, and Teams

NCT05572814
View directory record Official record
Conditions
Heart Failure, Type 2 Diabetes, Atrial Fibrillation
Interventions
Decision Support, Referral
Behavioral
Lead sponsor
American College of Cardiology
Other
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Amarillo, Texas
Source: ClinicalTrials.gov public record
Updated Oct 10, 2022 · Synced Oct 10, 2026, 2:35 PM EDT
Completed No phase listed Observational

Comparison of the Effectiveness and Tolerability of Exenatide Once-weekly Compared to Basal Insulins

NCT02974244
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
exenatide once weekly, basal insulin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 89 Years
Enrollment
7,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 29, 2017 · Synced Oct 10, 2026, 2:35 PM EDT
Completed Phase 1 Interventional

Drug Interaction Study Between Dorzagliatin and Empagliflozin

NCT03790787
View directory record Official record
Conditions
Patients
Interventions
Empagliflozin, Dorzagliatin
Drug
Lead sponsor
Hua Medicine Limited
Industry
Eligibility
30 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 10, 2026, 2:35 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)

NCT02585778
View directory record Official record
Conditions
Hypercholesterolaemia
Interventions
Alirocumab, Placebo, Lipid-Modifying Therapy (LMT), Antihyperglycemic Drug
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
517 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
29
States / cities
Encino, California • Fresno, California • Oakland, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Oct 10, 2026, 2:35 PM EDT
Completed Phase 1 Interventional

Phase 1 Study of FG-3019 in Subjects With Type 1 or Type 2 Diabetes Mellitus and Diabetic Nephropathy

NCT00754143
View directory record Official record
Conditions
Diabetes Mellitus, Diabetic Nephropathy
Interventions
FG-3019
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years to 80 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
18
States / cities
Birmingham, Alabama • Tempe, Arizona • La Mesa, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2019 · Synced Oct 10, 2026, 2:35 PM EDT
Completed Not applicable Interventional

Promoting Intergenerational Health in Rural Kentuckians With Diabetes (PIHRK'D)

NCT06080425
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Medical Nutrition Therapy
Behavioral
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 10, 2026, 2:35 PM EDT
Completed Phase 3 Interventional

Complaints Associated With Use of Pre-Filled Pen B With Type 2 Diabetics on Twice-Daily Insulin

NCT00231725
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
insulin lispro injection [rDNA origin] Low Mix
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
25 Years to 75 Years
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 27, 2007 · Synced Oct 10, 2026, 2:35 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How Different Amounts of PF-06954522 Are Tolerated and Act in Adults With Type 2 Diabetes Mellitus

NCT06279234
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2DM), Obesity
Interventions
Placebo, Rosuvastatin, Midazolam, Omeprazole, PF-06954522
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Anaheim, California • South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 3, 2025 · Synced Oct 10, 2026, 2:35 PM EDT
Completed Not applicable Interventional Results available

CGM Use in Children With Type 2 Diabetes

NCT04721158
View directory record Official record
Conditions
Type 2 Diabetes, Hyperglycemia Due to Type 2 Diabetes Mellitus
Interventions
Continuous glucose monitor
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
5 Years to 21 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 15, 2023 · Synced Oct 10, 2026, 2:35 PM EDT
Completed Not applicable Interventional

T-UP: Engaging Vulnerable Students in Diabetes Prevention

NCT06385015
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, PreDiabetes
Interventions
Tailored DPP Intervention
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
17 Years to 25 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 3, 2025 · Synced Oct 10, 2026, 2:35 PM EDT
Completed Phase 3 Interventional Results available

Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Older Patients With Type2 Diabetes Insufficiently Controlled on Their Current Antidiabetic Medications

NCT02320721
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Insulin Glargine (HOE901 - U300), Insulin Glargine (HOE901 - U100), Background therapy
Drug
Lead sponsor
Sanofi
Industry
Eligibility
65 Years and older
Enrollment
1,014 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
64
States / cities
Saraland, Alabama • Fresno, California • Greenbrae, California + 57 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2020 · Synced Oct 10, 2026, 2:35 PM EDT
Completed Not applicable Interventional Results available

Effect of Exenatide, Sitagliptin or Glimepiride on Functional ß -Cell Mass

NCT00775684
View directory record Official record
Conditions
Pre-diabetes, Type 2 Diabetes
Interventions
Exenatide, Sitagliptin, Glimepiride
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 70 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
3
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 7, 2022 · Synced Oct 10, 2026, 2:35 PM EDT
Completed Phase 3 Interventional

A Pilot Intervention Study of Health Coaching to Promote Diabetes Self-Care in the Community

NCT01695278
View directory record Official record
Conditions
Diabetes Complications, Diabetes Mellitus, Type 2
Interventions
Telephone Counseling
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 21, 2014 · Synced Oct 10, 2026, 2:35 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Renal HEIR Study: Renal Hemodynamics, Energetics and Insulin Resistance in Youth Onset Type 2 Diabetes Study

NCT03584217
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Obesity, Nephropathy, Adolescent Obesity
Interventions
Aminohippurate Sodium Inj 20%, Iohexol Inj 300 MG/ML, Renal Biopsy
Drug · Procedure
Lead sponsor
University of Colorado, Denver
Other
Eligibility
12 Years to 21 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 15, 2023 · Synced Oct 10, 2026, 2:35 PM EDT
Completed No phase listed Observational

Cancer in Patients on Dapagliflozin and Other Antidiabetic Treatment

NCT02695121
View directory record Official record
Conditions
Breast Cancer, Bladder Cancer
Interventions
Not listed
Lead sponsor
AstraZeneca
Industry
Eligibility
40 Years and older
Enrollment
2,133,575 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
2
States / cities
Wilmington, Delaware • Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Apr 17, 2026 · Synced Oct 10, 2026, 2:35 PM EDT
Completed Phase 3 Interventional

Study to Examine the Effect on Glucose Control and Safety/Tolerability of Exenatide Given Two Times a Day to Subjects With Type 2 Diabetes

NCT00111540
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
exenatide
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
60
States / cities
Birmingham, Alabama • Anaheim, California • Bellflower, California + 57 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2015 · Synced Oct 10, 2026, 2:35 PM EDT